These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 34033528)

  • 1. COVID-19 vaccine platforms: Delivering on a promise?
    Verdecia M; Kokai-Kun JF; Kibbey M; Acharya S; Venema J; Atouf F
    Hum Vaccin Immunother; 2021 Sep; 17(9):2873-2893. PubMed ID: 34033528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants.
    Chatterjee B; Thakur SS
    Expert Rev Vaccines; 2022 Jan; 21(1):47-67. PubMed ID: 34697980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines.
    Bayani F; Hashkavaei NS; Arjmand S; Rezaei S; Uskoković V; Alijanianzadeh M; Uversky VN; Ranaei Siadat SO; Mozaffari-Jovin S; Sefidbakht Y
    Prog Biophys Mol Biol; 2023 Mar; 178():32-49. PubMed ID: 36801471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microneedle technology for potential SARS-CoV-2 vaccine delivery.
    McNamee M; Wong S; Guy O; Sharma S
    Expert Opin Drug Deliv; 2023 Jun; 20(6):799-814. PubMed ID: 37128730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.
    Jafari A; Danesh Pouya F; Niknam Z; Abdollahpour-Alitappeh M; Rezaei-Tavirani M; Rasmi Y
    Mol Biol Rep; 2022 Jun; 49(6):4943-4957. PubMed ID: 35235159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines.
    Fernandes Q; Inchakalody VP; Merhi M; Mestiri S; Taib N; Moustafa Abo El-Ella D; Bedhiafi T; Raza A; Al-Zaidan L; Mohsen MO; Yousuf Al-Nesf MA; Hssain AA; Yassine HM; Bachmann MF; Uddin S; Dermime S
    Ann Med; 2022 Dec; 54(1):524-540. PubMed ID: 35132910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines against SARS-CoV-2 variants and future pandemics.
    Park T; Hwang H; Moon S; Kang SG; Song S; Kim YH; Kim H; Ko EJ; Yoon SD; Kang SM; Hwang HS
    Expert Rev Vaccines; 2022 Oct; 21(10):1363-1376. PubMed ID: 35924678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the vaccine development for the prophylaxis of SARS Covid-19.
    Kumar V; Kumar S; Sharma PC
    Int Immunopharmacol; 2022 Oct; 111():109175. PubMed ID: 35994853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
    Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
    Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 vaccines - the biggest medical research project of the 21st century.
    Kurup D; Schnell MJ
    Curr Opin Virol; 2021 Aug; 49():52-57. PubMed ID: 34049261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive aspects of the mRNA platform for SARS-CoV-2 vaccines.
    Hajissa K; Mussa A
    Hum Vaccin Immunother; 2021 Aug; 17(8):2445-2447. PubMed ID: 33830862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Landscape and progress of global COVID-19 vaccine development.
    Huang HY; Wang SH; Tang Y; Sheng W; Zuo CJ; Wu DW; Fang H; Du Q; Li N
    Hum Vaccin Immunother; 2021 Oct; 17(10):3276-3280. PubMed ID: 34254894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2.
    Jin Y; Hou C; Li Y; Zheng K; Wang C
    Front Immunol; 2021; 12():821538. PubMed ID: 35126377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).
    Alagheband Bahrami A; Azargoonjahromi A; Sadraei S; Aarabi A; Payandeh Z; Rajabibazl M
    Cell Mol Biol Lett; 2022 May; 27(1):38. PubMed ID: 35562685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.